• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Virol . The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus

tetano

Editor, Senior Moderator
J Virol


. 2021 Oct 20;JVI0096421.
doi: 10.1128/JVI.00964-21. Online ahead of print.
The K18-hACE2 Transgenic Mouse Model Recapitulates Non-Severe and Severe COVID-19 in Response to Infectious Dose of SARS-CoV-2 Virus


Wenjuan Dong[SUP] 1 2 [/SUP], Heather Mead[SUP] 3 [/SUP], Lei Tian[SUP] 1 [/SUP], Jun-Gyu Park[SUP] 4 [/SUP], Juan I Garcia[SUP] 4 [/SUP], Sierra Jaramillo[SUP] 3 [/SUP], Tasha Barr[SUP] 1 2 [/SUP], Daniel S Kollath[SUP] 3 [/SUP], Vanessa K Coyne[SUP] 3 [/SUP], Nathan E Stone[SUP] 3 [/SUP], Ashley Jones[SUP] 3 [/SUP], Jianying Zhang[SUP] 5 [/SUP], Aimin Li[SUP] 6 [/SUP], Li-Shu Wang[SUP] 7 [/SUP], Martha Milanes-Yearsley[SUP] 8 [/SUP], Jordi B Torrelles[SUP] 4 [/SUP], Luis Martinez-Sobrido[SUP] 4 [/SUP], Paul S Keim[SUP] 3 [/SUP], Bridget Marie Barker[SUP] 3 [/SUP], Michael A Caligiuri[SUP] 1 2 9 [/SUP], Jianhua Yu[SUP] 1 2 9 [/SUP]



Affiliations

Abstract

A comprehensive analysis and characterization of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection model that mimics non-severe and severe coronavirus disease 2019 (COVID-19) in humans is warranted for understating the virus and developing preventive and therapeutic agents. Here, we characterized the K18-hACE2 mouse model expressing human (h)ACE2 in mice, controlled by the human keratin 18 (K18) promoter, in the epithelia, including airway epithelial cells where SARS-CoV-2 infections typically start. We found that intranasal inoculation with higher viral doses (2×10[SUP]3[/SUP] and 2×10[SUP]4[/SUP] PFU) of SARS-CoV-2 caused lethality of all mice and severe damage of various organs, including lung, liver, and kidney, while lower doses (2×10[SUP]1[/SUP] and 2×10[SUP]2[/SUP] PFU) led to less severe tissue damage and some mice recovered from the infection. In this hACE2 mouse model, SARS-CoV-2 infection damaged multiple tissues, with a dose-dependent effect in most tissues. Similar damage was observed in post-mortem samples from COVID-19 patients. Finally, the mice that recovered from infection with a low dose of virus survived rechallenge with a high dose of virus. Compared to other existing models, the K18-hACE2 model seems to be the most sensitive COVID-19 model reported to date. Our work expands the information available about this model to include analysis of multiple infectious doses and various tissues with comparison to human post-mortem samples from COVID-19 patients. In conclusion, the K18-hACE2 mouse model recapitulates both severe and non-severe COVID-19 in humans being dose-dependent and can provide insight into disease progression and the efficacy of therapeutics for preventing or treating COVID-19. Importance The pandemic of coronavirus disease 2019 (COVID-19) has reached nearly 240 million cases and caused nearly 5 million deaths worldwide as of October 2021, has raised an urgent need for the development of novel drugs and therapeutics to prevent the spread and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To achieve this goal, an animal model that recapitulates the features of human COVID-19 disease progress and pathogenesis is greatly needed. In this study, we have comprehensively characterized a mouse model of SARS-CoV-2 infection using K18-hACE2 transgenic mice. We infected the mice with low and high doses of SARS-CoV-2 to study the pathogenesis and survival in response to different infection patterns. Moreover, we compared the pathogenesis of the K18-hACE2 transgenic mice with that of the COVID-19 patients to show that this model could be a useful tool for the development of anti-viral drugs and therapeutics.
 
Back
Top Bottom